{"article_title": "Good news for genomics startups: Illumina & Yuri Milner jump into the accelerator game", "article_keywords": ["genomics", "selected", "good", "accelerator", "milner", "money", "illumina", "companies", "jump", "game", "session", "program", "yuri", "nextgeneration", "sequencing", "startups", "technology"], "article_url": "http://medcitynews.com/2014/02/illumina-jumps-accelerator-game/", "article_text": "Next-generation sequencing has reached the \u201clift-off stage,\u201d according to Yuri Milner.\n\nHe\u2019s not just saying that; he\u2019s putting his money behind it. The famed tech investor is joining Illumina (NASDAQ:ILMN) in committing to helping early-stage genomics companies as part of a new Mission Bay accelerator.\n\nIllumina said today it\u2019s launching a program aimed at speeding up time-to-market and lowering barriers to entry for startups with promising next-generation sequencing applications.\n\nThe price of sequencing has come down tremendously as technology has advanced. (Illumina reminded us of that last month at the JP Morgan Healthcare Conference, when it revealed a new machine it said could sequence a full human genome for $1,000). That\u2019s opened the door for all kinds of new applications in agriculture, forensics, consumer genetics and diagnostics.\n\nAdvertisement\n\nEach session of Illumina\u2019s accelerator program will run for six months \u2013 a bit longer than many of the other health IT programs. Illumina will also take a 10 percent stake in each company.\n\nIn exchange, the selected companies get $100,000 in the form of access to lab space, instruments and reagents from Illumina, plus business and technology guidance. They\u2019ll also get access to Illumina\u2019s customer and venture networks, and banking services and credit from Silicon Valley Bank.\n\nAs an added bonus, selected companies will have the option of accepting $100,000 from Milner in exchange for convertible notes. Milner already has money in two genomics companies: GenapSys and 23andMe. Best known for his firm\u2019s investments in Facebook, Spotify, Twitter and Groupon, he\u2019s also an investor in digital health companies drchrono and First Opinion.\n\nTeams that apply for the accelerator can comprise up to five members who are researchers or entrepreneurs looking to bring an NGS application to market. The application period runs through May 16 for the first session beginning August 1.\n\n[Image credit: Flickr user Konrad Forstner]", "article_metadata": {"description": "Next-generation sequencing has reached the \u201clift-off stage,\u201d according to Yuri Milner. He\u2019s not just saying that; he\u2019s putting his money behind it. The famed tech investor is joining Illumina (NASDAQ:ILMN) in committing to helping early-stage genomics companies as part of a new Mission Bay accelerator. Illumina said today it\u2019s launching a program aimed at speeding up time-to-market and lowering barriers to entry for startups with promising next-generation sequencing applications. The price of sequencing has come down tremendously as technology has advanced. (Illumina reminded us of that last month at the JP Morgan Healthcare Conference, when it revealed a new machine it said could sequence a full human genome for $1,000). That\u2019s opened the door for all kinds of new applications in agriculture, forensics, consumer genetics and diagnostics. Each session of Illumina\u2019s accelerator program will run for six months \u2013 a bit longer than many of the other health IT programs. Illumina will also take a 10 percent stake in each company. In exchange, the selected companies get $100,000 in the form of access to lab space, instruments and reagents from Illumina, plus business and technology guidance. They\u2019ll also get access to Illumina\u2019s customer and venture networks, and banking services and credit from Silicon Valley Bank. As an added bonus, selected companies will have the option of accepting $100,000 from Milner in exchange for convertible notes. Milner already has money in two genomics companies: GenapSys and 23andMe. Best known for his firm\u2019s investments in Facebook, Spotify, Twitter and Groupon, he\u2019s also an investor in digital health companies drchrono and First Opinion. Teams that apply for the accelerator can comprise up to five members who are researchers or entrepreneurs looking to bring an NGS application to market. The application period runs through May 16 for the first session beginning August 1. [Image credit: Flickr user Konrad Forstner]", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Next-generation sequencing has reached the \u201clift-off stage,\u201d according to Yuri Milner. He\u2019s not just saying that; he\u2019s putting his money behind it. The famed tech investor is joining Illumina (NASDAQ:ILMN) in committing to helping early-stage genomics companies as part of a new Mission Bay accelerator. Illumina said today it\u2019s launching a program aimed at speeding up time-to-market and lowering barriers to entry for startups with promising next-generation sequencing applications. The price of sequencing has come down tremendously as technology has advanced. (Illumina reminded us of that last month at the JP Morgan Healthcare Conference, when it revealed a new machine it said could sequence a full human genome for $1,000). That\u2019s opened the door for all kinds of new applications in agriculture, forensics, consumer genetics and diagnostics. Each session of Illumina\u2019s accelerator program will run for six months \u2013 a bit longer than many of the other health IT programs. Illumina will also take a 10 percent stake in each company. In exchange, the selected companies get $100,000 in the form of access to lab space, instruments and reagents from Illumina, plus business and technology guidance. They\u2019ll also get access to Illumina\u2019s customer and venture networks, and banking services and credit from Silicon Valley Bank. As an added bonus, selected companies will have the option of accepting $100,000 from Milner in exchange for convertible notes. Milner already has money in two genomics companies: GenapSys and 23andMe. Best known for his firm\u2019s investments in Facebook, Spotify, Twitter and Groupon, he\u2019s also an investor in digital health companies drchrono and First Opinion. Teams that apply for the accelerator can comprise up to five members who are researchers or entrepreneurs looking to bring an NGS application to market. The application period runs through May 16 for the first session beginning August 1. [Image credit: Flickr user Konrad Forstner]", "title": "Good news for genomics startups: Illumina & Yuri Milner jump into the accelerator game", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/Illumina-MiSeq.jpg", "updated_time": "2016-01-13T12:09:38-04:00", "url": "http://medcitynews.com/2014/02/illumina-jumps-accelerator-game/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/Illumina-MiSeq.jpg", "description": "Next-generation sequencing has reached the \u201clift-off stage,\u201d according to Yuri Milner. He\u2019s not just saying that; he\u2019s putting his money behind it. The famed tech investor is joining Illumina (NASDAQ:ILMN) in committing to helping early-stage genomics companies as part of a new Mission Bay accelerator. Illumina said today it\u2019s launching a program aimed at speeding up time-to-market and lowering barriers to entry for startups with promising next-generation sequencing applications. The price of sequencing has come down tremendously as technology has advanced. (Illumina reminded us of that last month at the JP Morgan Healthcare Conference, when it revealed a new machine it said could sequence a full human genome for $1,000). That\u2019s opened the door for all kinds of new applications in agriculture, forensics, consumer genetics and diagnostics. Each session of Illumina\u2019s accelerator program will run for six months \u2013 a bit longer than many of the other health IT programs. Illumina will also take a 10 percent stake in each company. In exchange, the selected companies get $100,000 in the form of access to lab space, instruments and reagents from Illumina, plus business and technology guidance. They\u2019ll also get access to Illumina\u2019s customer and venture networks, and banking services and credit from Silicon Valley Bank. As an added bonus, selected companies will have the option of accepting $100,000 from Milner in exchange for convertible notes. Milner already has money in two genomics companies: GenapSys and 23andMe. Best known for his firm\u2019s investments in Facebook, Spotify, Twitter and Groupon, he\u2019s also an investor in digital health companies drchrono and First Opinion. Teams that apply for the accelerator can comprise up to five members who are researchers or entrepreneurs looking to bring an NGS application to market. The application period runs through May 16 for the first session beginning August 1. [Image credit: Flickr user Konrad Forstner]", "card": "summary", "title": "Good news for genomics startups: Illumina & Yuri Milner jump into the accelerator game - MedCity News"}, "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,accelerators, gene sequencing, Genomics, health IT, Illumina, Precision Medicine, San Francisco, Startups, , MedCity News", "article": {"section": "Convergence", "tag": "Startups", "published_time": "2014-02-12T15:14:18-04:00", "modified_time": "2016-01-13T12:09:38-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fe3a7a\"", "article_summary": "As an added bonus, selected companies will have the option of accepting $100,000 from Milner in exchange for convertible notes.\nNext-generation sequencing has reached the \u201clift-off stage,\u201d according to Yuri Milner.\nIllumina said today it\u2019s launching a program aimed at speeding up time-to-market and lowering barriers to entry for startups with promising next-generation sequencing applications.\nThe famed tech investor is joining Illumina (NASDAQ:ILMN) in committing to helping early-stage genomics companies as part of a new Mission Bay accelerator.\nIn exchange, the selected companies get $100,000 in the form of access to lab space, instruments and reagents from Illumina, plus business and technology guidance."}